Technology ID
TT-0135
Description
A next-generation, cutting-edge blood screening platform that integrates cell-free RNA (cfRNA) epitranscriptomics with AI to address a critical unmet need: accurate early detection of stage 0 colorectal cancer and pre-cancerous adenomas. Our platform enables a first-strike screening pathway that shifts care from reactive treatment to proactive, earliest detection.
Content
Pioneering Mechanism: Utilizes microbiome-derived cell-free RNA epitranscriptomics to capture dynamic tumor microenvironment fingerprints, offering a superior signal-to-noise ratio compared to traditional DNA tests
Superior Performance: AI-driven algorithms achieve a breakthrough 75% sensitivity for Stage 0 CRC and advanced adenomas, significantly outperforming current commercial blood and stool tests
High Accessibility: A non-invasive test requiring only 2 mL of blood, eliminating the need for dietary restrictions or bowel preparation, ensuring high patient compliance
Inventors
Applicable Industries
Potential Application
Technology Focus
TRL
Images
